netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Notes:

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

Chapter Links...
 Details...
03.03  Expand sub section  Cromoglicate, related therapy and leukotriene receptor antagonists
03.03.01  Expand sub section  Cromoglicate and related therapy
Sodium cromoglicate aerosol inhaler (Intal)
View adult BNF View SPC online
Formulary  
   
03.03.02  Expand sub section  Leukotriene receptor antagonists
Montelukast tabs
View adult BNF View SPC online
Formulary

 
Link  MHRA Sept 2019: Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions
   
Montelukast granules
View adult BNF View SPC online
Formulary  
   
03.03.03  Expand sub section  Phosphodiesterase type-4 inhibitors
Roflumilast tablets
View adult BNF View SPC online
Formulary
Amber 2
Approved as per NICE technology appraisal 461 
Link  NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

Amber 1

Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

Amber 2

Specialist initiation followed by maintenance prescribing in primary care  

Amber 3

Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

Green

Specialist and non-specialist initiation  

Grey

Not recommended for prescribing  

netFormulary